The experts will also discuss the clinical data on Covaxin from phase 1, 2, 3 trials and post marketing studies on safety, immunogenicity, efficacy and effectiveness, besides update on global, regional and country level plans for vaccine safety monitoring, the SAGE agenda said.from Industry-Economic Times
Read The Rest:economictimes...
